The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|July 11, 2016
Patheon Announces Initial Public Offering
Author(s)Pharmaceutical Technology Editors
Patheon launches initial public offering to repay outstanding notes and expenses.
Advertisement
Patheon announced on July 11, 2016, the commencement of the initial public offering of 30,487,805 of its ordinary shares for an expected price between $19.00 and $22.00 per share.
According to a statement, the company intends to use the proceeds of the sale and cash on hand to repay its outstanding $550 million of Senior PIK Toggle Notes, and pay related fees, expenses, and accrued interest.
The company is selling 25,609,756 ordinary shares and a selling stockholder is selling 4,878,049 ordinary shares. Patheon will not receive any proceeds from the sale of ordinary shares by the selling stockholder.
The ordinary shares of the company will be listed on the New York Stock Exchange under the symbol "PTHN".
In
Source:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Advertisement
Advertisement